Johnson & Johnson (NYSE:JNJ) Shares Sold by Beacon Investment Advisors LLC

Beacon Investment Advisors LLC lessened its position in shares of Johnson & Johnson (NYSE:JNJFree Report) by 49.2% in the 3rd quarter, HoldingsChannel reports. The fund owned 3,068 shares of the company’s stock after selling 2,966 shares during the period. Beacon Investment Advisors LLC’s holdings in Johnson & Johnson were worth $478,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Hibernia Wealth Partners LLC acquired a new position in Johnson & Johnson during the 3rd quarter worth approximately $27,000. FNY Investment Advisers LLC acquired a new position in Johnson & Johnson during the 3rd quarter worth approximately $37,000. Tower View Wealth Management LLC boosted its holdings in shares of Johnson & Johnson by 183.3% in the 3rd quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock valued at $40,000 after buying an additional 165 shares in the last quarter. Creative Capital Management Investments LLC boosted its holdings in shares of Johnson & Johnson by 43.0% in the 3rd quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock valued at $45,000 after buying an additional 86 shares in the last quarter. Finally, VitalStone Financial LLC acquired a new position in shares of Johnson & Johnson in the 2nd quarter valued at $48,000. Institutional investors and hedge funds own 68.40% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. TheStreet cut shares of Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday, November 17th. Royal Bank of Canada restated an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday, January 24th. Morgan Stanley lowered their target price on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a report on Wednesday, January 24th. Raymond James upped their price target on shares of Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research report on Wednesday, January 3rd. Finally, Wells Fargo & Company downgraded shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $170.00 to $163.00 in a research report on Wednesday, December 13th. Eight research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $176.14.

Check Out Our Latest Analysis on Johnson & Johnson

Johnson & Johnson Stock Up 0.2 %

Shares of Johnson & Johnson stock opened at $156.74 on Friday. The company has a market cap of $377.32 billion, a P/E ratio of 11.35, a PEG ratio of 2.65 and a beta of 0.53. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.96 and a current ratio of 1.21. Johnson & Johnson has a one year low of $144.95 and a one year high of $175.97. The firm has a fifty day moving average of $158.20 and a two-hundred day moving average of $158.93.

Johnson & Johnson (NYSE:JNJGet Free Report) last announced its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, topping analysts’ consensus estimates of $2.28 by $0.01. The company had revenue of $21.40 billion during the quarter, compared to the consensus estimate of $21.02 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 36.75%. Johnson & Johnson’s quarterly revenue was down 9.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.35 EPS. On average, analysts forecast that Johnson & Johnson will post 10.66 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th will be paid a $1.19 dividend. The ex-dividend date of this dividend is Friday, February 16th. This represents a $4.76 dividend on an annualized basis and a yield of 3.04%. Johnson & Johnson’s payout ratio is 34.47%.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.